Navigation Links
Protein predicts Gleevec resistance in gastrointestinal tumors
Date:5/15/2008

Excess amounts of a protein called IGF-1R in patients with gastrointestinal stromal tumors (GISTs) could indicate that the patient would be less responsive to the drug imatinib mesylate (known as Gleevec), according to Andrew K. Godwin, Ph.D., a researcher at the Fox Chase Cancer Center in Philadelphia. Preliminary studies have shown that GIST cells, especially Gleevec-resistant cells, might respond well to agents in development for treatment-resistant breast cancer, a form of breast cancer also marked by excessive production of the IGF-1R protein. IGF-1R could also serve as a marker to identify this subset of GIST patients before therapy begins, when alternative treatments would be most effective, the researcher says.

Godwin presents his findings at the 2008 Annual Meeting of the American Society of Clinical Oncology, held May 30 through June 3 in Chicago.

A small percentage of adult gastrointestinal stromal tumors and most pediatric cases are often less responsive to Gleevec, says Godwin, Director of Fox Chase's Clinical Molecular Genetics Laboratory. We have found that tumors in many of these cases coincide with an overabundance of the IGF-1R protein.

In most occurrences, GISTs develop through a mutation in the genes c-KIT or PDGFRα, both of which are targets of Gleevec. GISTs without those mutations, known as wild type, as well as pediatric GISTs, do not often respond well to treatment with Gleevec.

The Fox Chase researchers found that, when compared to mutant GISTs, the DNA of wild type and pediatric GISTs exhibited more copies of the IGF1R gene. These tumors also produced many more copies of the IGF-1R protein, which serves to promote cell survival, proliferation and growth in normal cells. In tumors, an excess of IGF-1R allows cancer cells to grow out of control, breaking the normal control mechanisms that are an inherent part of cell function. In the laboratory, the researchers found that drugs that decrease IGF-1R activity induced the death of tumor cells.

According to Godwin and his colleagues, their studies are the first to reveal that the development of wild type GISTs could be related to abnormal expression of IGF-1R.

IGF-1R overproduction seems to be a common factor in a number of different cancers, and there are several IGF-1R-targeted therapeutic agents in development and in clinical trials that might also be effective against GISTs, Godwin says. As is often the case with targeted therapies, we need to find the right patient for the drug as much as we need to find the right drug for the disease.

Godwin and his colleagues will soon publish the full results of their studies and have begun investigating the possibility of testing for IGF-1R in clinical trials at Fox Chase.


'/>"/>

Contact: Greg Lester
gregory.lester@fccc.edu
215-728-2753
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Carnegie Mellon engineering researchers automate analysis of protein patterns
2. Virus mimics human protein to hijack cell division machinery
3. Naturally-occuring protein may be effective in limiting heart attack injury and restoring function
4. Scientists identify interacting proteins key to melanoma development, treatment
5. Double duty: Loss of protective heart failure protein causes high blood pressure
6. Protein May Trigger Colon Cancer
7. Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk
8. First atomic-level look at a protein that causes brain disease
9. OHSU Cancer Institute researcher identifies protein that helps predict prostate cancer survival
10. Detour(R) Unveils Snack Size Protein Bar
11. Genome analysis reveals new protein associated with breast cancer progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... The American ... review more than eighty-nine grant submissions all vying for nearly $1,000,000 in funding ... Parkinson’s field.     , The American Parkinson Disease Association (APDA) is focused on advancing ...
(Date:5/26/2017)... ... May 26, 2017 , ... Somnoware, a leading provider of ... with its Somnoware Sleep Device Interface (SDI). Somnoware SDI is a sleep device ... this platform, initializing devices and importing studies are just one-click operations. This plugin ...
(Date:5/26/2017)... ... 2017 , ... On May 24, the Congressional Budget Office (CBO) projected that ... May 4, would result in 23 million Americans losing their health insurance by 2026 ... Protection and Affordable Care Act (ACA). , “It is clear from the CBO ...
(Date:5/26/2017)... , ... May 26, 2017 , ... Rob Lowe acts ... upcoming production of the series is on hiking in American. Viewers can reconnect with ... the great benefits of hiking. , Many consumers have looked for an inventive new ...
(Date:5/26/2017)... ... May 26, 2017 , ... Centennial-based ... of proceeds from its 14th Annual Clays for Kids fundraiser, to be held ... Bennett, Colorado. , As part of BluSky’s partnership with The Adoption Exchange, ...
Breaking Medicine News(10 mins):
(Date:5/24/2017)... Va. , May 24, 2017  ivWatch ... Original Equipment Manufacturer (OEM) Board to enable seamless ... with patient monitoring systems, infusion pumps and other ... OEMs will be able to help health care ... and reduced risks related to IV therapy. ...
(Date:5/22/2017)... May 22, 2017  Lilac Corp, the company ... the launch of a new website . ... of a clinical study that showed surprising clearance ... Gene-Eden-VIR/Novirin in individuals suffering from HPV warts, precancerous, ... there are no other treatments that clear the ...
(Date:5/18/2017)... WHIPPANY, N.J. , May 18, 2017  Two ... Healthcare Businesswomen,s Association (HBA) during its recent 28 th ... New York City.  The event showcases HBA,s longstanding mission ... the business of healthcare. Cindy Powell-Steffen ... in Bayer,s U.S. Radiology division, and Libby Howe ...
Breaking Medicine Technology: